Early 18ffluorodeoxyglucose positron emission tomographybased response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: A children's oncology group report

Peter D. Cole; Kathleen M. McCarten; Richard A. Drachtman; Pedro De Alarcon; Lu Chen; Tanya M. Trippett; Cindy L. Schwartz

doi:10.3109/08880018.2010.504250

Early ¹⁸ffluorodeoxyglucose positron emission tomographybased response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: A children's oncology group report

Peter D. Cole, Kathleen M. McCarten, Richard A. Drachtman, Pedro De Alarcon, Lu Chen, Tanya M. Trippett, Cindy L. Schwartz

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.

Original language	English (US)
Pages (from-to)	650-657
Number of pages	8
Journal	Pediatric Hematology and Oncology
Volume	27
Issue number	8
DOIs	https://doi.org/10.3109/08880018.2010.504250
State	Published - Oct 18 2010
Externally published	Yes

Keywords

Gemcitabine
Hodgkin disease
Phase 2 trial
Positron emission tomography
Treatment response
Vinorelbine

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.3109/08880018.2010.504250

Cite this

Cole, P. D., McCarten, K. M., Drachtman, R. A., Alarcon, P. D., Chen, L., Trippett, T. M., & Schwartz, C. L. (2010). Early ¹⁸ffluorodeoxyglucose positron emission tomographybased response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: A children's oncology group report. Pediatric Hematology and Oncology, 27(8), 650-657. https://doi.org/10.3109/08880018.2010.504250

Early ¹⁸ffluorodeoxyglucose positron emission tomographybased response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: A children's oncology group report. / Cole, Peter D.; McCarten, Kathleen M.; Drachtman, Richard A. et al.
In: Pediatric Hematology and Oncology, Vol. 27, No. 8, 18.10.2010, p. 650-657.

Research output: Contribution to journal › Article › peer-review

Cole, PD, McCarten, KM, Drachtman, RA, Alarcon, PD, Chen, L, Trippett, TM & Schwartz, CL 2010, 'Early ¹⁸ffluorodeoxyglucose positron emission tomographybased response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: A children's oncology group report', Pediatric Hematology and Oncology, vol. 27, no. 8, pp. 650-657. https://doi.org/10.3109/08880018.2010.504250

@article{4c577b03bea54451a54bde61d1b799d6,

title = "Early 18ffluorodeoxyglucose positron emission tomographybased response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: A children's oncology group report",

abstract = "The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.",

keywords = "Gemcitabine, Hodgkin disease, Phase 2 trial, Positron emission tomography, Treatment response, Vinorelbine",

author = "Cole, {Peter D.} and McCarten, {Kathleen M.} and Drachtman, {Richard A.} and Alarcon, {Pedro De} and Lu Chen and Trippett, {Tanya M.} and Schwartz, {Cindy L.}",

note = "Funding Information: This research is supported by the Chair{\textquoteright}s Grant U10 CA98543 and the Statistics and Data Center Grant U10 CA98413 of the Children{\textquoteright}s Oncology Group from the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. A complete listing of grant support for research conducted by CCG and POG before initiation of the COG grant in 2003 is available online at: http://www.childrensoncoogygroup.org/admin/grantinfo.htm.",

year = "2010",

month = oct,

day = "18",

doi = "10.3109/08880018.2010.504250",

language = "English (US)",

volume = "27",

pages = "650--657",

journal = "Pediatric Hematology and Oncology",

issn = "0888-0018",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - Early 18ffluorodeoxyglucose positron emission tomographybased response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease

T2 - A children's oncology group report

AU - Cole, Peter D.

AU - McCarten, Kathleen M.

AU - Drachtman, Richard A.

AU - Alarcon, Pedro De

AU - Chen, Lu

AU - Trippett, Tanya M.

AU - Schwartz, Cindy L.

N1 - Funding Information: This research is supported by the Chair’s Grant U10 CA98543 and the Statistics and Data Center Grant U10 CA98413 of the Children’s Oncology Group from the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. A complete listing of grant support for research conducted by CCG and POG before initiation of the COG grant in 2003 is available online at: http://www.childrensoncoogygroup.org/admin/grantinfo.htm.

PY - 2010/10/18

Y1 - 2010/10/18

N2 - The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.

AB - The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.

KW - Gemcitabine

KW - Hodgkin disease

KW - Phase 2 trial

KW - Positron emission tomography

KW - Treatment response

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=77958051538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958051538&partnerID=8YFLogxK

U2 - 10.3109/08880018.2010.504250

DO - 10.3109/08880018.2010.504250

M3 - Article

C2 - 20863157

AN - SCOPUS:77958051538

SN - 0888-0018

VL - 27

SP - 650

EP - 657

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

IS - 8

ER -